Exalenz Of Israel, Pfizer Of U.S. In Deal With FDA-Approved Test Kit
This article was originally published in PharmAsia News
Israel's Exalenz Bioscience has signed a replacement deal with U.S.-based Pfizer to use the BreathID noninvasive diagnostic kit to test Pfizer drugs for treating gastrointestinal disorders
You may also be interested in...
Cancer immunotherapy biotech Leap, backed by HealthCare Ventures and Lilly, reverse-merges with Israel's Macrocure. Elite and SunGen will partner to develop generic versions of four drugs that posted $3bn in aggregate sales over a recent 12-month stretch.
Pharma’s opponents believe passage of the Inflation Reduction Act represents a momentum shift that will make it easier for politicians (even some Republicans) to take on the industry. They’ll need to count on that as they still have a long list of targets ahead on their lower-drug pricing agenda.
Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.